139,658 Shares in Day One Biopharmaceuticals, Inc. $DAWN Acquired by Nuveen LLC

Nuveen LLC bought a new stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 139,658 shares of the company's stock, valued at approximately $1,107,000. Nuveen LLC owned 0.14% of Day One Biopharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its stake in shares of Day One Biopharmaceuticals by 10.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 927,017 shares of the company's stock worth $11,745,000 after buying an additional 90,822 shares during the last quarter. MetLife Investment Management LLC increased its stake in shares of Day One Biopharmaceuticals by 12.4% during the 4th quarter. MetLife Investment Management LLC now owns 34,248 shares of the company's stock valued at $434,000 after acquiring an additional 3,781 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Day One Biopharmaceuticals by 911.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company's stock worth $135,000 after purchasing an additional 9,603 shares during the period. Hsbc Holdings PLC purchased a new stake in shares of Day One Biopharmaceuticals during the 4th quarter worth about $481,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in shares of Day One Biopharmaceuticals during the 4th quarter worth about $219,000. Institutional investors and hedge funds own 87.95% of the company's stock.

Insiders Place Their Bets

In other news, CEO Jeremy Bender sold 16,058 shares of Day One Biopharmaceuticals stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $6.77, for a total transaction of $108,712.66. Following the completion of the sale, the chief executive officer directly owned 161,365 shares in the company, valued at $1,092,441.05. The trade was a 9.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Adam Dubow sold 4,365 shares of Day One Biopharmaceuticals stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $6.77, for a total value of $29,551.05. Following the sale, the insider owned 54,858 shares of the company's stock, valued at approximately $371,388.66. This represents a 7.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 28,295 shares of company stock worth $191,557. Insiders own 6.20% of the company's stock.

Day One Biopharmaceuticals Trading Down 0.9%

NASDAQ:DAWN traded down $0.07 on Thursday, hitting $7.41. 640,227 shares of the company's stock traded hands, compared to its average volume of 1,364,391. Day One Biopharmaceuticals, Inc. has a 1 year low of $5.64 and a 1 year high of $16.76. The firm has a 50-day moving average price of $6.78 and a 200-day moving average price of $7.38. The company has a market cap of $759.01 million, a PE ratio of -7.80 and a beta of -1.25.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.06. Day One Biopharmaceuticals had a negative return on equity of 19.01% and a negative net margin of 50.63%.The company had revenue of $33.91 million for the quarter, compared to analysts' expectations of $35.55 million. On average, research analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on DAWN shares. HC Wainwright decreased their price target on Day One Biopharmaceuticals from $36.00 to $25.00 and set a "buy" rating for the company in a report on Wednesday, August 6th. Needham & Company LLC lowered their price target on Day One Biopharmaceuticals from $18.00 to $16.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. Wedbush reaffirmed an "outperform" rating and set a $25.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. Finally, Piper Sandler assumed coverage on Day One Biopharmaceuticals in a research note on Monday, August 18th. They issued an "overweight" rating and a $25.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $25.29.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.